Want to see CLB full AI Analyst Report?
Top Page
Core Laboratories
(NYSE:CLB)
Select Model
Select Model
Rating:60Neutral
Price Target:
$10.50
▼(-6.50% Downside)
Action:Reiterated
Date:07/30/26
The score is driven mainly by steady-but-mixed financial performance (stronger balance sheet and positive FCF, but softer TTM revenue/earnings and uneven cash conversion) and a constructive earnings outlook for sequential improvement despite notable geopolitical and operational headwinds. This is partially offset by weak technicals, with the stock trading well below key moving averages. Valuation is reasonable with a modest dividend yield, but it is not strong enough to outweigh the bearish trend.
Positive Factors
Improved leverage and stronger balance sheet
Material de-leveraging and steady equity growth reduce financial risk and increase strategic optionality. With lower net leverage (~1.3x in Q2) the company can better withstand oilfield cyclicality, fund rebuilds and contracts, and sustain capital returns without compromising liquidity over the medium term.
Negative Factors
Year-over-year revenue and earnings decline
Sustained YoY declines signal weaker demand or lost large instrumentation sales, reducing revenue visibility and compressing profitability. If this trend persists it limits internal reinvestment and could force trade-offs between capex, R&D commercialization and shareholder returns, weakening long-term growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage and stronger balance sheet
Material de-leveraging and steady equity growth reduce financial risk and increase strategic optionality. With lower net leverage (~1.3x in Q2) the company can better withstand oilfield cyclicality, fund rebuilds and contracts, and sustain capital returns without compromising liquidity over the medium term.
Read all positive factors
Core Laboratories Key Performance Indicators (KPIs)
Any
Revenue By Segment
Shows how different business segments contribute to overall revenue, highlighting which areas drive growth and profitability for Core Laboratories.
Shows how different business segments contribute to overall revenue, highlighting which areas drive growth and profitability for Core Laboratories.
Data provided by:
The Fly
The FlyCore Laboratories (CLB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$488.21M
Dividend Yield0.38%
Average Volume (3M)411.26K
Price to Earnings (P/E)19.0
Beta (1Y)1.20
Revenue Growth0.35%
EPS GrowthN/A
CountryUS
Employees3,300
SectorEnergy
Sector Strength52
IndustryOil & Gas Equipment & Services
Share Statistics
EPS (TTM)0.56
Shares Outstanding45,884,540
10 Day Avg. Volume423,711
30 Day Avg. Volume411,263
Financial Highlights & Ratios
PEG Ratio15.79
Price to Book (P/B)2.80
Price to Sales (P/S)1.42
P/FCF Ratio33.44
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$11.00Price Target Upside-2.05% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)0.47
Revenue Forecast (FY)$513.14M
Core Laboratories Business Overview & Revenue Model
Company Description
Core Laboratories N.V. (CLB) is a global provider to the oil and gas sector, delivering specialized services and products for characterizing subterranean reservoirs and optimizing hydrocarbon extraction. The company's operations are distinctly seg...
How the Company Makes Money
Core Laboratories makes money by selling specialized technical services and related products to oil and gas companies, with revenue primarily generated on a fee-for-service/project basis and, in some cases, through ongoing service arrangements tie...
Core Laboratories Earnings Call Summary
Earnings Call Date:Jul 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 28, 2026
Earnings Call Sentiment Positive
The call highlighted clear sequential improvements in revenue, margins, product sales, and operating profitability, a constructive Q3 outlook, continued technology commercialization and disciplined capital returns. However, year-over-year revenue and earnings declined, with significant near-term headwinds from geopolitical conflicts (Middle East and Russia/Ukraine) adversely affecting assay and service work and forcing ongoing cost carry and regional operating challenges. Management emphasizes operational resilience, technology adoption, and shareholder returns while guiding for sequential growth into Q3.Positive Updates
Sequential Revenue Growth
Q2 revenue of $124.6M, up >2% sequentially, indicating sequential recovery despite YoY weakness.
Negative Updates
Year-over-Year Revenue Decline
Q2 revenue decreased 4% year-over-year to $124.6M, reflecting weaker demand in affected regions and the absence of some large instrumentation sales from the prior year.
Read all updates
Q2-2026 Updates
Positive
Negative
Sequential Revenue Growth
Q2 revenue of $124.6M, up >2% sequentially, indicating sequential recovery despite YoY weakness.
Read all positive updates
Company Guidance
Core Labs guided Q3 2026 consolidated revenue of $128.5–$135.5 million (midpoint $132.0M) and operating income of $10.5–$15.0 million (midpoint $12.75M), implying overall operating margins of ~10%, with EPS of $0.12–$0.20 (midpoint $0.16). By segment, Reservoir Description is projected at $81–$84M revenue with $5.5–$7.9M operating income, and Production Enhancement at $47.5–$51.5M revenue with $4.8–$6.9M operating income. Management expects sequential revenue growth driven by mid‑single‑digit strength in Reservoir Description (Africa, Brazil, Asia‑Pacific, South Atlantic) and mid‑single to low‑double‑digit growth in Production Enhancement (modest U.S. land improvement and slightly higher international product sales). Guidance excludes FX gains/losses, assumes a 25% effective tax rate, and is given alongside FY 2026 expectations of G&A ~$43–$45M and capital expenditures (ex U.K. rebuild) of $15–$18M.Core Laboratories Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 519.18M | 526.52M | 523.85M | 509.79M | 489.74M | 470.25M |
| Gross Profit | 94.06M | 94.28M | 88.37M | 94.05M | 78.92M | 83.84M |
| EBITDA | 62.65M | 71.12M | 73.51M | 70.42M | 58.69M | 63.78M |
| Net Income | 24.35M | 29.67M | 31.40M | 36.67M | 19.45M | 19.73M |
Balance Sheet | ||||||
| Total Assets | 586.78M | 584.01M | 590.41M | 586.39M | 578.35M | 580.85M |
| Cash, Cash Equivalents and Short-Term Investments | 22.73M | 22.70M | 19.16M | 15.12M | 15.43M | 17.70M |
| Total Debt | 165.12M | 164.02M | 180.14M | 215.38M | 222.39M | 250.26M |
| Total Liabilities | 308.01M | 311.80M | 332.67M | 356.59M | 389.40M | 419.85M |
| Stockholders Equity | 272.67M | 265.99M | 251.99M | 224.81M | 184.26M | 156.45M |
Cash Flow | ||||||
| Free Cash Flow | 10.73M | 22.29M | 43.36M | 14.21M | 14.74M | 23.04M |
| Operating Cash Flow | 28.22M | 37.03M | 56.39M | 24.79M | 24.96M | 36.58M |
| Investing Cash Flow | -8.68M | -2.23M | -6.39M | -6.65M | -3.86M | -10.22M |
| Financing Cash Flow | -27.99M | -31.25M | -45.96M | -18.45M | -23.38M | -22.46M |
Core Laboratories Technical Analysis
Positive
11.23
Price Trends
11.80
Negative
13.67
Negative
15.32
Negative
Market Momentum
-0.21
Negative
50.80
Neutral
72.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLB, the sentiment is Positive. The current price of 11.23 is above the 20-day moving average (MA) of 11.17, below the 50-day MA of 11.80, and below the 200-day MA of 15.32, indicating a neutral trend. The MACD of -0.21 indicates Negative momentum. The RSI at 50.80 is Neutral, neither overbought nor oversold. The STOCH value of 72.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLB.
Core Laboratories Peers Comparison
UnderperformOutperform
Sector (65)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $851.62M | 28.23 | 28.83% | ― | 24.72% | 72.35% | |
65 Neutral | $15.17B | 7.61 | 4.09% | 5.20% | 3.87% | -62.32% | |
60 Neutral | $488.21M | 19.00 | 9.03% | 0.34% | 0.35% | ― | |
59 Neutral | $1.13B | 113.40 | 1.95% | ― | 4.09% | -93.54% | |
56 Neutral | $488.17M | -4.33 | -17.80% | ― | -2.80% | -1752.76% | |
56 Neutral | $1.36B | -98.23 | -1.49% | ― | -15.14% | 92.26% | |
50 Neutral | $730.92M | -1.52 | -55.10% | ― | -18.94% | -69.29% |
* Energy Sector Average
CLB
Core Laboratories
11.35
1.63
16.76%
FTK
Flotek
35.42
21.56
155.56%
OIS
Oil States International
8.14
3.15
63.13%
TTI
Tetra Technologies
8.51
4.59
117.09%
PUMP
Propetro Holding
10.98
6.28
133.62%
ACDC
ProFrac Holding
4.32
-1.77
-29.06%
Core Laboratories Corporate Events
Business Operations and StrategyStock BuybackDividendsFinancial Disclosures
Core Laboratories Reports Mixed Q2 2026 Results, Boosts Liquidity
Neutral
Jul 29, 2026
On July 29, 2026, Core Laboratories reported second quarter 2026 revenue of $124.6 million, up 2% sequentially but down 4% year-on-year, with GAAP operating income of $9.2 million and earnings per share of $0.13. Free cash flow reached $3.1 millio...
Executive/Board ChangesShareholder Meetings
Core Laboratories Shareholders Back Directors, Auditor and Pay
Positive
May 13, 2026
Core Laboratories Inc. held its Annual Meeting of Shareholders on May 12, 2026, in Houston, Texas, where investors considered director elections, auditor ratification, and executive compensation matters. Shareholders re-elected Class I directors H...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.